Marta Tellez-Gabriel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2823558/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cancer stem cells in osteosarcoma. Cancer Letters, 2017, 386, 189-195.	7.2	224
2	Circulating Tumor Cells: A Review of Non–EpCAM-Based Approaches for Cell Enrichment and Isolation. Clinical Chemistry, 2016, 62, 571-581.	3.2	196
3	Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis. International Journal of Molecular Sciences, 2016, 17, 2142.	4.1	129
4	Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. Journal of Bone Oncology, 2015, 4, 1-12.	2.4	116
5	Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity. Theranostics, 2019, 9, 4580-4594.	10.0	69
6	ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis. Cancer Research, 2016, 76, 3236-3251.	0.9	48
7	Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine. Cancers, 2019, 11, 19.	3.7	48
8	Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?. Drug Discovery Today, 2019, 24, 763-772.	6.4	46
9	The Challenges of Detecting Circulating Tumor Cells in Sarcoma. Frontiers in Oncology, 2016, 6, 202.	2.8	21
10	Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy. Journal of Bone Oncology, 2018, 12, 83-90.	2.4	20
11	CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advancedâ€stage head and neck squamous cell carcinoma. Head and Neck, 2016, 38, E1392-403.	2.0	16
12	Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. Journal of Translational Medicine, 2017, 15, 115.	4.4	16
13	Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip. European Journal of Cell Biology, 2017, 96, 110-118.	3.6	11
14	The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelialâ€like head and neck carcinoma subtypes. Head and Neck, 2019, 41, 1830-1845.	2.0	9
15	Liquid biopsy in bone sarcomas and identification of new biomarkers. , 2022, , 487-500.		0